Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
HKD 0.14
(1.41%)
HKD 0.14
(1.41%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 402.99 Million CNY | 16.59% |
| 2022 | 370.27 Million CNY | 6.45% |
| 2021 | 347.84 Million CNY | -34.55% |
| 2020 | 531.5 Million CNY | -6.93% |
| 2019 | 571.07 Million CNY | 29.13% |
| 2018 | 442.24 Million CNY | 24.52% |
| 2017 | 355.15 Million CNY | 19.62% |
| 2016 | 296.89 Million CNY | -2.1% |
| 2015 | 303.26 Million CNY | 44.95% |
| 2014 | 209.21 Million CNY | 2.92% |
| 2013 | 203.29 Million CNY | 37.08% |
| 2012 | 148.3 Million CNY | 22.54% |
| 2011 | 121.02 Million CNY | 339.11% |
| 2010 | 27.56 Million CNY | 2.88% |
| 2009 | 26.79 Million CNY | -20.91% |
| 2008 | 33.87 Million CNY | 13.26% |
| 2007 | 29.9 Million CNY | -15.52% |
| 2006 | 35.4 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 82.55 Million CNY | -33.73% |
| 2024 Q2 | 62.05 Million CNY | -24.84% |
| 2023 Q2 | 92.44 Million CNY | -22.38% |
| 2023 FY | 431.72 Million CNY | 16.59% |
| 2023 Q3 | 95.6 Million CNY | 3.42% |
| 2023 Q1 | 119.09 Million CNY | 6.14% |
| 2023 Q4 | 124.57 Million CNY | 30.31% |
| 2022 FY | 370.27 Million CNY | 6.45% |
| 2022 Q4 | 112.2 Million CNY | 18.44% |
| 2022 Q1 | 83.31 Million CNY | -17.69% |
| 2022 Q2 | 85.07 Million CNY | 2.1% |
| 2022 Q3 | 94.73 Million CNY | 11.36% |
| 2021 Q1 | 98.98 Million CNY | -32.42% |
| 2021 Q4 | 101.23 Million CNY | 24.22% |
| 2021 Q3 | 81.49 Million CNY | 24.71% |
| 2021 FY | 347.84 Million CNY | -34.55% |
| 2021 Q2 | 65.35 Million CNY | -33.98% |
| 2020 Q4 | 146.46 Million CNY | -8.83% |
| 2020 FY | 531.5 Million CNY | -6.93% |
| 2020 Q1 | 80.88 Million CNY | -45.52% |
| 2020 Q2 | 143.5 Million CNY | 77.41% |
| 2020 Q3 | 160.64 Million CNY | 11.95% |
| 2019 Q3 | 154.46 Million CNY | -0.93% |
| 2019 Q2 | 155.91 Million CNY | 38.63% |
| 2019 FY | 571.07 Million CNY | 29.13% |
| 2019 Q1 | 112.46 Million CNY | 1.65% |
| 2019 Q4 | 148.47 Million CNY | -3.88% |
| 2018 Q1 | 97.17 Million CNY | -22.04% |
| 2018 FY | 442.24 Million CNY | 24.52% |
| 2018 Q4 | 110.64 Million CNY | -6.2% |
| 2018 Q3 | 117.95 Million CNY | 2.27% |
| 2018 Q2 | 115.33 Million CNY | 18.69% |
| 2017 FY | 355.15 Million CNY | 19.62% |
| 2017 Q3 | 89.99 Million CNY | 12.2% |
| 2017 Q2 | 80.21 Million CNY | 34.23% |
| 2017 Q1 | 59.75 Million CNY | -33.17% |
| 2017 Q4 | 124.64 Million CNY | 38.5% |
| 2016 Q1 | 55.99 Million CNY | -49.07% |
| 2016 Q2 | 80.12 Million CNY | 43.08% |
| 2016 Q3 | 71.51 Million CNY | -10.74% |
| 2016 FY | 296.89 Million CNY | -2.1% |
| 2016 Q4 | 89.42 Million CNY | 25.04% |
| 2015 Q1 | 47.3 Million CNY | -31.03% |
| 2015 Q2 | 72.55 Million CNY | 53.39% |
| 2015 FY | 303.26 Million CNY | 44.95% |
| 2015 Q4 | 109.94 Million CNY | 51.69% |
| 2015 Q3 | 72.48 Million CNY | -0.1% |
| 2014 FY | 209.21 Million CNY | 2.92% |
| 2014 Q2 | 51.4 Million CNY | 19.59% |
| 2014 Q4 | 68.58 Million CNY | 48.31% |
| 2014 Q3 | 46.24 Million CNY | -10.04% |
| 2014 Q1 | 42.98 Million CNY | -36.43% |
| 2013 FY | 203.29 Million CNY | 37.08% |
| 2013 Q4 | 67.61 Million CNY | 35.55% |
| 2013 Q1 | 45.77 Million CNY | -13.2% |
| 2013 Q3 | 49.88 Million CNY | 25.07% |
| 2013 Q2 | 39.88 Million CNY | -12.87% |
| 2012 Q2 | 30.38 Million CNY | -4.32% |
| 2012 Q4 | 52.73 Million CNY | 56.29% |
| 2012 Q3 | 33.74 Million CNY | 11.07% |
| 2012 Q1 | 31.75 Million CNY | -42.67% |
| 2012 FY | 148.3 Million CNY | 22.54% |
| 2011 Q3 | 13.47 Million CNY | -46.02% |
| 2011 FY | 121.02 Million CNY | 339.11% |
| 2011 Q1 | 31.23 Million CNY | 12798.37% |
| 2011 Q2 | 24.95 Million CNY | -20.11% |
| 2011 Q4 | 55.39 Million CNY | 311.13% |
| 2010 Q1 | 5.4 Million CNY | -35.49% |
| 2010 FY | 27.56 Million CNY | 2.88% |
| 2010 Q4 | -246 Thousand CNY | -101.44% |
| 2010 Q3 | 17.07 Million CNY | 228.85% |
| 2010 Q2 | 5.19 Million CNY | -3.87% |
| 2009 Q2 | 5.97 Million CNY | 0.0% |
| 2009 Q3 | 8.8 Million CNY | 47.22% |
| 2009 FY | 26.79 Million CNY | -20.91% |
| 2009 Q4 | 8.37 Million CNY | -4.86% |
| 2008 FY | 33.87 Million CNY | 13.26% |
| 2007 FY | 29.9 Million CNY | -15.52% |
| 2006 FY | 35.4 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | -1549.996% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 89.562% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -1034.334% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | -13.862% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | -2256.42% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | 31.81% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | 67.209% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | 19.955% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -86.03% |
| SSY Group Limited | 1.98 Billion HKD | 79.654% |
| JBM (Healthcare) Limited | 163.87 Million HKD | -145.915% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | -40.246% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 98.627% |